OTCPK:DMSI

Stock Analysis Report

Executive Summary

Dermisonics, Inc. manufactures ultrasonic transdermal drug-delivery technologies and equipment.

Snowflake

Fundamentals

Adequate balance sheet with weak fundamentals.

Risks

  • Dermisonics has significant price volatility in the past 3 months.
  • Dermisonics's last earnings update was 4414 days ago.
  • Dermisonics is not covered by any analysts.
  • Dermisonics is a small market cap stock, these often have low liquidity.

Share Price & News

How has Dermisonics's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

0%

DMSI

0.7%

US Medical Equipment

-0.2%

US Market


1 Year Return

-100.0%

DMSI

9.5%

US Medical Equipment

1.1%

US Market

DMSI underperformed the Medical Equipment industry which returned 9.9% over the past year.

DMSI underperformed the Market in United States of America which returned 1.6% over the past year.


Share holder returns

DMSIIndustryMarket
7 Day0%0.7%-0.2%
30 Day-99.0%0.1%2.5%
90 Day0%2.5%1.6%
1 Year-100.0%-100.0%10.4%9.5%3.4%1.1%
3 Year-99.9%-99.9%69.3%64.1%45.2%35.8%
5 Year-100.0%-100.0%138.0%110.9%62.6%44.8%

Price Volatility Vs. Market

How volatile is Dermisonics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Dermisonics undervalued based on future cash flows and its price relative to the stock market?


In this section, we usually try to help investors determine whether Dermisonics is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Dermisonics has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Next Steps

  • Examine Dermisonics's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  • When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through Dermisonics regulatory filings here.
  • Explore potentially undervalued companies in the Healthcare industry.

Future Growth

How is Dermisonics expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

22.5%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Dermisonics has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Dermisonics performed over the past 5 years?

0.2%

Historical Healthcare annual earnings growth


In this section we usually display a company’s past earnings and revenues to help investors visualise the trend through time. We also gauge the company’s performance by benchmarking its returns and growth to its industry peers and the wider market. However, Dermisonics has not provided sufficient past data to assess its track record.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have historical data.


Next Steps

Financial Health

How is Dermisonics's financial position?


In this section we usually analyse Dermisonics's finance health to determine how well-positioned it is against times of financial distress, in particular, its ability to manage its cash and debt levels. Dermisonics has not provided adequate balance sheet data, its financial health cannot be properly assessed as it.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have financial information.


Next Steps

  • Take a look at our analysis of DMSI’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • Investors tend to look at the financial health of a company this size in order to assess the sustainability of its current operations. While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website.
  • Financial health is measured at one point in time, so the latest financial report is the best representation of the company’s current financial status. Check when Dermisonics's financial data was last updated here.
  • Explore more healthy companies in the Healthcare industry.

Dividend

What is Dermisonics's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Dermisonics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Dermisonics's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Dermisonics has not reported any payouts.

Unable to verify if Dermisonics's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Dermisonics has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of Dermisonics's salary, the management and board of directors tenure and is there insider trading?

13.8yrs

Average board tenure


CEO

Bruce Haglund (67yo)

0yrs

Tenure

0

Mr. Bruce H. Haglund, Esq., J.D., has been Executive Chairman of Dermisonics, Inc., since August 6, 2004 and serves as its Chief Executive Officer, Acting Principal Financial Officer and Acting Principal A ...


Board Age and Tenure

13.8yrs

Average Tenure

The average tenure for the Dermisonics board of directors is over 10 years, this suggests they are a seasoned and experienced board.


Insider Trading

No 3 month open market individual insider trading information.


Management Team

  • Bruce Haglund (67yo)

    Executive Chairman

    • Tenure: 0yrs

Board Members

  • Bruce Haglund (67yo)

    Executive Chairman

    • Tenure: 0yrs
  • Bruce Redding (66yo)

    Director

    • Tenure: 13.2yrs
    • Compensation: US$154.17k
  • Theodore van de Kamp

    Member of Advisory Board

    • Tenure: 13.8yrs
  • Adil Saleh

    Member of Business Advisory Council

    • Tenure: 0yrs

Company Information

Dermisonics, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Dermisonics, Inc.
  • Ticker: DMSI
  • Exchange: OTCPK
  • Founded: 2000
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: US$63.000
  • Shares outstanding: 63.91m
  • Website: https://null

Location

  • Dermisonics, Inc.
  • 2 Park Plaza
  • Suite 450
  • Irvine
  • California
  • 92614
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
DMSIOTCPK (Pink Sheets LLC)YesCommon StockUSUSDMay 2002

Biography

Dermisonics, Inc. manufactures ultrasonic transdermal drug-delivery technologies and equipment. It primarily focuses on the development, testing, and commercialization of its active transdermal patch, call ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/20 00:28
End of Day Share Price2019/09/04 00:00
Earnings2007/06/30
Annual Earnings2006/09/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.